Overview
The Global Carglumic Acid Market (https://market.us/report/carglumic-acid-market/) was valued at USD 217.7 million in 2025 and is projected to expand at a CAGR of 6.3% from 2026 to 2035, reaching approximately USD 400.8 million by 2035. North America dominated the market in 2025, capturing more than 38.3% of the global share and generating around USD 83.38 million in revenue. Carglumic acid is an orphan medicine used to treat hyperammonemia associated with N-acetylglutamate synthase (NAGS) deficiency and selected organic acidemias, supporting long-term management of rare metabolic disorders. According to the U.S. National Library of Medicine, MedlinePlus Genetics (2024), urea cycle disorders (UCDs) occur in approximately 1 in 35,000 to 1 in 51,946 live births, while NAGS deficiency affects fewer than 1 in 2,000,000 live births, highlighting the highly specialized nature of the market.
The market continues to benefit from improvements in genetic testing, newborn screening, and rare disease awareness, enabling earlier diagnosis and treatment. Available as 200 mg tablets for oral suspension, carglumic acid is suitable for both pediatric and adult patients. Growing investment in rare disease healthcare, expanding specialist treatment centres, and increasing access to metabolic disorder therapies are expected to support steady market growth through 2035.
Key Takeaways
The Global Carglumic Acid Market was valued at US$ 217.7 million in 2025.
The market is projected to grow at a CAGR of 6.3% during the forecast period, reaching an estimated value of US$ 400.8 million by 2035.
Tablets dominated the formulation type segment with a 65.4% share.
Urea cycle disorders led the application segment with a 57.2% share.
Hospital pharmacies dominated the distribution channel segment with a 48.5% share.
Hospitals led the end-use segment with a 52.7% share.
North America dominated the regional market with a 38.3% share.
Carglumic Acid Market Segmentation
Formulation Type Analysis
Tablets Represent the Dominant Segment in the Market
Tablets dominate the carglumic acid market with a 65.4% share, driven by the need for lifelong treatment of N-acetylglutamate synthase (NAGS) deficiency. Tablets provide convenient, accurate dosing and are suitable for home-based care, while 200 mg dispersible tablets can be divided into four 50 mg doses and dispersed in at least 2.5 mL of water, making them suitable for pediatric and adult patients. According to the FDA Prescribing Information (February 2024), carglumic acid (C₆H₁₀N₂O₅) has a molecular weight of 190.16 g/mol and is slightly soluble in cold water, supporting its dispersible tablet formulation.
Application Analysis
Urea Cycle Disorders Represent the Dominant Application Segment in the Market
Urea cycle disorders (UCDs) account for 57.2% of total carglumic acid demand, as the drug is the primary treatment for NAGS deficiency, helping restore the urea cycle and reduce toxic ammonia levels. Since untreated UCDs can lead to severe neurological damage, coma, or death, demand remains stable due to clinical necessity. Meanwhile, the use of carglumic acid in liver disorders is expanding as research explores its potential to manage ammonia buildup associated with liver failure.
Distribution Channel Analysis
Hospital Pharmacy Represents the Dominant Distribution Channel in the Market
Hospital pharmacies lead the market with a 48.5% share, reflecting the specialized care required for rare metabolic disorders. Diagnosis, treatment initiation, emergency management, and ongoing monitoring of urea cycle disorders are primarily conducted in hospitals, making them the main dispensing channel. Online pharmacies are the fastest-growing segment, driven by increasing demand for convenient home delivery and long-term prescription management for rare disease patients.
End User Analysis
Hospitals Represent the Dominant End User Segment in the Market
Hospitals account for 52.7% of total end-user demand due to their central role in diagnosing and managing NAGS deficiency and acute hyperammonemia. According to the FDA Prescribing Information (January 2024), treatment data from 23 patients showed that, among 13 evaluable patients, mean plasma ammonia levels decreased from 271 µmol/L at baseline to 181 µmol/L on Day 1 and 27 µmol/L on Day 3. The FDA also recommends close ammonia monitoring under specialist supervision, reinforcing hospitals as the primary treatment setting.
Key Market Segments
By Formulation Type
Tablet
Oral Solution
Injection
By Application
Urea Cycle Disorders
Liver Disorders
Pharmacological Research
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By End Use
Hospitals
Specialty Clinics
Research Laboratories
Others
Driver Analysis
Earlier Diagnosis of NAGS Deficiency and UCD Pathways
Earlier diagnosis of N-acetylglutamate synthase (NAGS) deficiency and urea cycle disorders (UCDs) is driving demand for carglumic acid. The U.S. indication recommends treatment as soon as NAGS deficiency is suspected, with acute dosing of 100–250 mg/kg/day and chronic dosing of 10–100 mg/kg/day. HHS supports universal newborn screening through the RUSP, while NIH recommends screening at 24–48 hours after birth. According to NIH, UCDs occur in around 1 in 35,000 live births in the U.S., equivalent to approximately 113 new patients annually, supporting gradual market growth through earlier diagnosis.
Restraint Analysis
High Orphan Drug Price Inflation & HTA Pressure
High treatment costs and stricter Health Technology Assessment (HTA) policies continue to limit market growth. Carglumic acid therapy can exceed USD 250,000 per patient annually, with orphan drugs typically priced 3–5 times higher than non-orphan specialty medicines. European reimbursement thresholds have tightened to around EUR 50,000–80,000 per QALY, extending HTA reviews by 6–12 months, resulting in 10–20% price renegotiations over 5 years, 300–500 basis points margin pressure, and reducing effective demand in EU and UK markets to 80–85% of clinical need. Net prices are also expected to decline by 2–3% annually, creating an estimated 2.2 percentage point drag on CAGR.
Opportunity Analysis
Multi-Indication Orphan Expansion
Expanding carglumic acid into additional orphan indications offers significant growth potential. The current NAGS deficiency population is estimated at around 0.00125 per 10,000 people in the EU, supporting a global market of approximately USD 150–250 million. Clinical development for 2–3 additional orphan indications with incidence rates of 1–3 per 100,000 live births could increase treated patients by 3–5 times, assuming 40–60% market penetration. Label expansions by 2030 could generate an additional USD 150–300 million in market opportunity and contribute around +2.0 percentage points to CAGR.
Challenges Analysis
Cold-Chain and Logistics Fragility
Cold-chain and logistics challenges remain a key barrier for carglumic acid distribution. Shipments to secondary and tertiary markets often require 10–20 days, compared with 3–7 days for standard generics, while 5–8% of shipments experience temperature deviations or administrative delays. These issues can reduce product shelf life by 10–20% and increase distribution costs by 8–12%, creating an estimated 0.8 percentage point drag on CAGR. Manufacturers are addressing these challenges through validated packaging, route optimization, 2–3 logistics partners per region, and digital licensing systems to reduce customs delays by 2–4 days over the next 2–4 years.
Key Development
In February 2026, Novartis AG completed the Avidity acquisition at an enterprise value of about USD 11 billion. Novartis reported Q1 sales of USD 13.113 billion and free cash flow of USD 3.330 billion, showing strong financial capacity to invest further in specialized medicines. In October 2025, Apothecon Pharmaceuticals announced a new manufacturing facility at Sayakha, Gujarat, equipped with peptide and finished-dosage-form production lines and an annual capacity of 1 billion tablets and capsules. This expansion strengthens the company’s ability to manufacture specialty oral medicines, including its 200 mg carglumic acid tablets for oral suspension, which are used for acute and chronic hyperammonemia caused by NAGS deficiency.
Top comments (0)